Table 2.
Outcome | β | p |
---|---|---|
Asthma inflammation composite (baseline) | ||
SES | −.355 | <.001 |
Shift-and-persist | −.083 | .403 |
SES × shift-and-persist | .187 | .047 |
Asthma impairment (at 6 month follow up) | ||
SES | −.273 | .006 |
Shift-and-persist | −.160 | .109 |
SES × shift-and-persist | .315 | .001 |
Peak flow variability (at 6 month follow up) | ||
SES | −.014 | .899 |
Shift-and-persist | −.017 | .881 |
SES × shift-and-persist | .186 | .084 |
Note: All analyses control for child age, gender, ethnicity, asthma severity, inhaled corticosteroid use, beta agonist use. In addition, analyses that predicted outcomes at 6 month follow up controlled for baseline values. The asthma inflammation composite is a standardized score reflecting eosinophil counts and stimulated IL-4 production. The asthma impairment measure is a composite reflecting the percentage of days of school absences and rescue inhaler use during the 2 week daily diary assessment. Peak flow variability was calculated based on 2 weeks of morning and evening peak flow readings.